- SynonymERBB2,CD340,HER-2/neu,HER2,MLN19,NEU,NGL,TKR1
- SourceHuman Her2, His Tag (HE2-H5225) is expressed from human 293 cells (HEK293). It contains AA Thr 23 - Thr 652 (Accession # P04626-1).Predicted N-terminus: Thr 23Request for sequence
- Molecular Characterization
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 70.2 kDa. The protein migrates as 110-115 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
- EndotoxinLess than 1.0 EU per μg by the LAL method.
- Purity
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
- Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
- Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
- Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 12 months under sterile conditions after reconstitution.
Human Her2, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
The purity of Human Her2, His Tag (Cat. No. HE2-H5225) was more than 90% and the molecular weight of this protein is around 80-95 kDa verified by SEC-MALS.
Immobilized Human Her2, His Tag (Cat. No. HE2-H5225) at 0.05 μg/mL (100 μL/well) can bind Trastuzumab with a linear range of 0.2-3 ng/mL (QC tested).
Immobilized Human Her2, His Tag (Cat. No. HE2-H5225) at 1 μg/mL (100 μL/well) can bind Pertuzumab with a linear range of 0.2-3 ng/mL (Routinely tested).
Herceptin (Trastuzumab) captured on CM5 chip via anti-human IgG Fc antibodies surface, can bind Human Her2, His Tag (Cat. No. HE2-H5225) with an affinity constant of 1.07 nM as determined in a SPR assay (Biacore T200) (Routinely tested).
Loaded Herceptin (Trastuzumab) on AHC Biosensor, can bind Human Her2, His Tag (Cat. No. HE2-H5225) with an affinity constant of 0.825 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
- Citations
Single-step Protein A and Protein G avidity purification methods to support bispecific antibody discovery and development
Authors: Ollier R, et al
Journal: MAbs 2019
Application: SPR
Request for Full-text
Bispecific antibodies targeting egfr and her2
Authors: E Zhukovsky, et al
Journal: US20190153104A1 2019
Application: SPR
Request for Full-text
Cryo-EM Structure of HER2-trastuzumab-pertuzumab complex
Authors: Hao Y, et al
Journal: PLoS One 2019
Application: Protein purification
Request for Full-text
A viral nanoparticle cancer vaccine delays tumor progression and prolongs survival in a HER2+ tumor mouse model
Authors: S Shukla, et al
Journal: Adv Ther 2019
Application: ELISA
Request for Full-text
Isolation and characterization of camelid single-domain antibodies against HER2
Authors: Hussack G, et al
Journal: BMC Res Notes 2018
Application: Immunization & SPR
Request for Full-text
Cytidine-5-carboxamide modified nucleotide compositions and methods related thereto
Authors: J Rohloff et al.
Journal: US9938314B2 2018
Application: SELEX
Request for Full-text
Afucosylated protein, cell expressing said protein and associated methods
Authors: S Chatterjee, et al.
Journal: US20180171028A1 2018
Application: ELISA
Request for Full-text
Glutamic acid-valine-citrulline linkers ensure stability and efficacy of antibody-drug conjugates in mice
Authors: Anami Y, et al.
Journal: Nat Commun 2018
Application: ELISA
Request for Full-text
Fluorine-18 labeling of an anti-HER2 VHH using a residualizing prosthetic group via a strain-promoted click reaction: Chemistry and preliminary evaluation
Authors: Zhou Z, et al.
Journal: Bioorg Med Chem 2018
Application:
Request for Full-text
Anti-HER2 scFv-directed extracellular vesicle-mediated mRNA-based gene delivery inhibits growth of HER2-positive human breast tumor xenografts by prodrug activation
Authors: Wang JH, et al.
Journal: Mol Cancer Ther 2018
Application: ELISA
Request for Full-text
Development of NanoLuc bridging immunoassay for detection of anti-drug antibodies
Authors: Nath N, et al.
Journal: J Immunol Methods 2017
Application: ELISA
Request for Full-text
Efficient generation of single domain antibodies with high affinities and enhanced thermal stabilities
Authors: Shinozaki N, et al.
Journal: Sci Rep 2017
Application: Rabbit immunization
Request for Full-text
Quantification of circulating cancer biomarkers via sensitive topographic measurements on single binder nanoarrays
Authors: Elena Ambrosetti, et al.
Journal: ACS Omega 2017
Application: Multiplex detection & SPR & AFM & ELISA
Request for Full-text
LEAPS vaccine incorporating HER-2/neu epitope elicits protection that prevents and limits tumor growth and spread of breast cancer in a mouse model
Authors: Ken S. Rosenthal, et al.
Journal: J Immunol Res 2017
Application: ELISA
Request for Full-text
Charge variant analysis of proposed biosimilar to Trastuzumab
Authors: Dakshinamurthy P, et al.
Journal: Biologicals 2017
Application: SPR
Request for Full-text
Plant viral nanoparticles-based HER2 vaccine: Immune response influenced by differential transport, localization and cellular interactions of particulate carriers
Authors: S Shukla, et al.
Journal: Biomaterials 2016
Application: ELISA
Request for Full-text
Determination of drug-to-antibody ratio for antibody-drug conjugates purified from serum
Authors: Chen J, et al.
Journal: Agilent 2016
Application:
Request for Full-text
Monoclonal antibodies against HER2 epitope and methods of use thereof
Authors: Natalya D Bodyak, et al.
Journal: US20150366987A1 2015
Application: ELISA
Request for Full-text
Quantification of antibody production of individual hybridoma cells by Surface Plasmon Resonance imaging
Authors: Stojanović I, et al.
Journal: Anal Biochem 2015
Application: SPR
Request for Full-text
Tumor cell targeting by iron oxide nanoparticles is dominated by different factors in vitro versus in vivo
Authors: NDong C, et al.
Journal: PLoS One 2015
Application: ELISA
Request for Full-text
- BackgroundHuman Epidermal growth factor Receptor 2 (HER2) is also called ERBB2, HER-2,HER-2 /neu, NEU, NGL,TKR1 and c-erb B2,and is a protein giving higher aggressiveness in breast cancers. It is a member of the ErbB protein family, more commonly known as the epidermal growth factor receptor family. HER2 is a cell membrane surface-bound receptor tyrosine kinase and is normally involved in the signal transduction pathways leading to cell growth and differentiation. HER2 is thought to be an orphan receptor, with none of the EGF family of ligands able to activate it. Approximately 30% of breast cancers have an amplification of the HER2 gene or overexpression of its protein product. Overexpression of this receptor in breast cancer is associated with increased disease recurrence and worse prognosis. HER2 appears to play roles in development, cancer, communication at the neuromuscular junction and regulation of cell growth and differentiation .
- References
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.
